Not Available
Opzelura® cream
$1,600.00
Not Available
The US Food and Drug Administration (FDA) approved ruxolitinib (Opzelura) cream 1.5% for the treatment of nonsegmental vitiligo in adults and pediatric patients 12 years and older, making it the first FDA-approved treatment for repigmentation of the skin in patients with the condition. It is not currently available for sale in Canada.
